146 related articles for article (PubMed ID: 1826187)
1. Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group.
Lehtonen A
Am Heart J; 1991 Apr; 121(4 Pt 2):1307-11. PubMed ID: 1826187
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
Talseth T; Westlie L; Daae L; Vatle S
Am Heart J; 1988 Dec; 116(6 Pt 2):1790-6. PubMed ID: 2904752
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
Trost BN; Weidmann P; Riesen W; Claessens J; Streulens Y; Nelemans F
Am J Cardiol; 1987 May; 59(14):99G-104G. PubMed ID: 2884861
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive effect of doxazosin and atenolol in short- and long-term double-blind comparison.
Lijnen P; Fagard R; Staessen J; Amery A
Methods Find Exp Clin Pharmacol; 1990 Oct; 12(8):563-73. PubMed ID: 2151197
[TBL] [Abstract][Full Text] [Related]
5. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
Torvik D; Madsbu HP
Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
[TBL] [Abstract][Full Text] [Related]
6. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension.
Torvik D; Madsbu HP
Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):69S-75S. PubMed ID: 2939870
[TBL] [Abstract][Full Text] [Related]
7. Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.
Frick MH; Cox DA; Himanen P; Huttunen M; Pitkäjärvi T; Pörsti P; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P
Am J Cardiol; 1987 May; 59(14):61G-67G. PubMed ID: 2884854
[TBL] [Abstract][Full Text] [Related]
8. Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins.
Lehtonen A; Himanen P; Saraste M; Niittymäki K; Marniemi J
Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):77S-81S. PubMed ID: 2939871
[TBL] [Abstract][Full Text] [Related]
9. Long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension.
Lijnen P; Fagard R; Staessen J; Lissens W; Amery A
J Cardiovasc Pharmacol; 1989 Aug; 14(2):319-25. PubMed ID: 2476608
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with doxazosin in general medical practice.
Rosenthal J
Am Heart J; 1988 Dec; 116(6 Pt 2):1748-57. PubMed ID: 2904745
[TBL] [Abstract][Full Text] [Related]
11. Doxazosin in the treatment of patients with mild or moderate hypertension and mild or moderate renal insufficiency.
Bartels AC; de Vries PM; Oe LP; van Bronswÿk H; Donker AJ; Réveillaud RJ; Fillastre JP; Zech P
Am Heart J; 1988 Dec; 116(6 Pt 2):1772-7. PubMed ID: 2904749
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension.
Giorgi G; Legramante JM; Fioravanti G; Paies G; Legramante A
Am Heart J; 1988 Dec; 116(6 Pt 2):1801-5. PubMed ID: 2904754
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
14. Doxazosin versus atenolol: a randomized comparison of calculated coronary heart disease risk reduction.
Mazzola C; Guerrasio E
Am Heart J; 1988 Dec; 116(6 Pt 2):1797-801. PubMed ID: 2904753
[TBL] [Abstract][Full Text] [Related]
15. A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension.
Frick MH; Halttunen P; Himanen P; Huttunen M; Pörsti P; Pitkäjärvi T; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P
Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):55S-62S. PubMed ID: 2939868
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol.
Baez MA; Garg DC; Jallad NS; Weidler DJ
Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):63S-67S. PubMed ID: 2939869
[TBL] [Abstract][Full Text] [Related]
17. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism.
Pool JL
Am Heart J; 1991 Jan; 121(1 Pt 2):251-9; discussion 259-60. PubMed ID: 1824647
[TBL] [Abstract][Full Text] [Related]
18. Doxazosin: a study in a cohort of patients with hypertension in general practice--an interim report.
Langdon CG
Am Heart J; 1991 Jan; 121(1 Pt 2):268-73. PubMed ID: 1824649
[TBL] [Abstract][Full Text] [Related]
19. A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
Castrignano R; D'Angelo A; Pati T; Al Awady M; Tronca R; Crepaldi G
Am Heart J; 1988 Dec; 116(6 Pt 2):1778-84. PubMed ID: 2904750
[TBL] [Abstract][Full Text] [Related]
20. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
Rosenthal J
Am Heart J; 1988 Dec; 116(6 Pt 2):1763-6. PubMed ID: 2904747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
